

## Special Issue

# Pharmacogenetics of Treating Anxiety & Depression

### Message from the Guest Editor

Pharmacogenetics has the potential to improve the treatment of anxiety and depression. Though some institutions have been implementing pharmacogenetics in the clinical care of patients with anxiety and depression for many years, there is still much more research to be done. The aim of this Special Issue is to provide a comprehensive overview of how pharmacogenetics can influence the efficacy and tolerability of medications used to treat anxiety and depression, the current state of research in this area, and the challenges and opportunities for implementation in clinical care. Articles may be in the areas of discovery, replication, trial design, position papers, meta-analyses, or a description of your implementation. Articles may be in the form of research article, review paper, or communication.

---

### Guest Editor


Dr. Laura B. Ramsey

1. Divisions of Clinical Pharmacology & Research in Patient Services, Cincinnati, OH 45229, USA
2. Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
3. College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA

---

### Deadline for manuscript submissions

closed (31 March 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/76279](https://mdpi.com/si/76279)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

---

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).